Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Intravoxel Incoherent Motion Diffusion-weighted MRI Assessing the Effect of the Vascular Disrupting Agent CA4P on VX2 Liver Tumors in Rabbits

Author(s): Ting Qian*, Rong Yang*, Yuzhe Wang* and Qingqing Duan

Volume 20, 2024

Published on: 27 April, 2023

Article ID: e060323214365 Pages: 9

DOI: 10.2174/1573405619666230306110835

open_access

Abstract

Objective: This study aimed to assess the response of combretastatin-A4-phosphate (CA4P) in rabbit VX2 liver tumors using intravoxel incoherent motion diffusion-weighted MRI (IVIM DW-MRI).

Methods: Forty rabbits with implanted VX2 liver tumors underwent baseline MRI and were then given 10 mg/kg CA4P (n=20) or saline (n=20). After 4 h, 10 rabbits from each group underwent an MRI examination and were then sacrificed. The remaining rabbits underwent MRI after 1, 3, and 7 days and were then sacrificed. Liver samples were processed for H&E and immunohistochemical staining. IVIM parameters (D, f, D*) were compared in the treatment and control groups, and the correlations of IVIM parameters with microvascular density (MVD) were determined.

Results: At 4 h, the two treatment groups had significantly different f and D* values (p<0.001), and these values were at their minimum in the treatment group. The treatment group had moderate correlations between MVD and f at 4 h (r=0.676, p=0.032) and 7 days (r=0.656, p=0.039) and with D* at 4 h (r=0.732, p=0.016) and 7 days (r=0.748, p=0.013), but no correlation was reported between MVD and f or D* in the control group (all P>0.05).

Conclusion: IVIM DW-MRI is a sensitive imaging technique. It successfully evaluated the effect of CA4P on VX2 liver tumors in rabbits. The f and D* values correlated with MVD at 4 h and 7 days after using CA4P, indicating that these parameters have the potential to be used as indicators of tumor angiogenesis after treatment.

Keywords: Rabbits, Intravoxel incoherent motion diffusion-weighted magnetic resonance imaging (IVIM-DW-MRI), Liver neoplasms, Vascular disrupting agent (VDA), Microvascular density (MVD), VX2 tumor.

[1]
Öz A, Server S, Koyuncu Sökmen B, Namal E, İnan N, Balcı NC. Intravoxel incoherent motion of colon cancer liver metastases for the assessment of response to antiangiogenic treatment: Results from a pilot study. Med Princ Pract 2020; 29(5): 429-35.
[http://dx.doi.org/10.1159/000505814] [PMID: 31914438]
[2]
Abou Elkassem AM, Lo SS, Gunn AJ, et al. Role of imaging in renal cell carcinoma: A multidisciplinary perspective. Radiographics 2021; 41(5): 1387-407.
[http://dx.doi.org/10.1148/rg.2021200202] [PMID: 34270355]
[3]
Chen J, Qian T, Zhang H, Wei C, Meng F, Yin H. Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model. Magn Reson Imaging 2016; 34(2): 177-82.
[http://dx.doi.org/10.1016/j.mri.2015.10.013] [PMID: 26518059]
[4]
Qian T, Chen M, Gao F, Meng F, Gao X, Yin H. Diffusion-weighted magnetic resonance imaging to evaluate microvascular density after transarterial embolization ablation in a rabbit VX2 liver tumor model. Magn Reson Imaging 2014; 32(8): 1052-7.
[http://dx.doi.org/10.1016/j.mri.2014.05.011] [PMID: 24970024]
[5]
Shi Y, Oeh J, Hitz A, et al. Monitoring and targeting Anti-VEGF induced hypoxia within the viable tumor by 19 F–MRI and multispectral analysis. Neoplasia 2017; 19(11): 950-9.
[http://dx.doi.org/10.1016/j.neo.2017.07.010] [PMID: 28987998]
[6]
Feraco P, Scartoni D, Porretti G, et al. Predict treatment response by magnetic resonance diffusion weighted imaging: A preliminary study on 46 meningiomas treated with proton-therapy. Diagnostics 2021; 11(9): 1684.
[http://dx.doi.org/10.3390/diagnostics11091684] [PMID: 34574025]
[7]
Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168(2): 497-505.
[http://dx.doi.org/10.1148/radiology.168.2.3393671] [PMID: 3393671]
[8]
Le Bihan DJ. Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: A closer step toward the "holy grail" of tissue characterization? Radiology 1998; 207(2): 305-7.
[9]
Lee HJ, Rha SY, Chung YE, et al. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: Correlation with histological microvessel density. Magn Reson Med 2014; 71(4): 1554-8.
[http://dx.doi.org/10.1002/mrm.24810] [PMID: 23798038]
[10]
Dolciami M, Capuani S, Celli V, et al. Intravoxel Incoherent Motion (IVIM) MR Quantification in Locally Advanced Cervical Cancer (LACC): Preliminary study on assessment of tumor aggressiveness and response to neoadjuvant chemotherapy. J Pers Med 2022; 12(4): 638.
[http://dx.doi.org/10.3390/jpm12040638] [PMID: 35455755]
[11]
Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology 2014; 272(2): 417-26.
[http://dx.doi.org/10.1148/radiol.14131165] [PMID: 24697148]
[12]
Xiao-ping Y, Jing H, Fei-ping L, et al. Intravoxel incoherent motion MRI for predicting early response to induction chemotherapy and chemoradiotherapy in patients with nasopharyngeal carcinoma. J Magn Reson Imaging 2016; 43(5): 1179-90.
[http://dx.doi.org/10.1002/jmri.25075] [PMID: 26540374]
[13]
Karayama M, Yoshizawa N, Sugiyama M, et al. Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer. Lung Cancer 2020; 143: 47-54.
[http://dx.doi.org/10.1016/j.lungcan.2020.03.013] [PMID: 32203770]
[14]
Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kabbinavar F. A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. OncoTargets Ther 2016; 9: 7275-83.
[http://dx.doi.org/10.2147/OTT.S109186] [PMID: 27942221]
[15]
Zweifel M, Jayson GC, Reed NS, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; 22(9): 2036-41.
[http://dx.doi.org/10.1093/annonc/mdq708] [PMID: 21273348]
[16]
Shi C, Liu D, Xiao Z, et al. Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI. Cancer research 2017; 77(13): 3491-501.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-2499]
[17]
Cheng J, Wang Y, Zhang CF, et al. Chemotherapy response evaluation in a mouse model of gastric cancer using intravoxel incoherent motion diffusion-weighted MRI and histopathology. World J Gastroenterol 2017; 23(11): 1990-2001.
[http://dx.doi.org/10.3748/wjg.v23.i11.1990] [PMID: 28373765]
[18]
Liu Y, De Keyzer F, Wang Y, et al. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats. Int J Cancer 2018; 143(7): 1817-28.
[http://dx.doi.org/10.1002/ijc.31567] [PMID: 29707770]
[19]
Liu Y, Guan Q, Kong X, et al. Predicting therapeutic efficacy of vascular disrupting agent CA4P in rats with liver tumors by hepatobiliary contrast agent Mn-DPDP-enhanced MRI. Transl Oncol 2020; 13(1): 92-101.
[http://dx.doi.org/10.1016/j.tranon.2019.09.010] [PMID: 31810003]
[20]
Shao H, Ni Y, Zhang J, et al. Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors. PLoS One 2013; 8(12): e82649.
[http://dx.doi.org/10.1371/journal.pone.0082649] [PMID: 24376560]
[21]
Shao H, Ni Y, Dai X, et al. Diffusion-weighted MR imaging allows monitoring the effect of combretastatin A4 phosphate on rabbit implanted VX2 tumor model: 12-Day dynamic results. Eur J Radiol 2012; 81(3): 578-83.
[http://dx.doi.org/10.1016/j.ejrad.2011.03.009] [PMID: 21454029]
[22]
Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36(2): 169-80.
[http://dx.doi.org/10.1007/BF00666038] [PMID: 8534865]
[23]
Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: Dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237(2): 492-9.
[http://dx.doi.org/10.1148/radiol.2372041638]
[24]
Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: Application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161(2): 401-7.
[http://dx.doi.org/10.1148/radiology.161.2.3763909] [PMID: 3763909]
[25]
Luo J, Zhou K, Zhang B, Luo N, Bian J. Intravoxel incoherent motion diffusion-weighted imaging for evaluation of the cell density and angiogenesis of cirrhosis-related nodules in an experimental rat model: Comparison and correlation with dynamic contrast-enhanced MRI. J Magn Reson Imaging 2020; 51(3): 812-23.
[http://dx.doi.org/10.1002/jmri.26845] [PMID: 31245888]
[26]
Li Y, Wang Z, Chen F, et al. Intravoxel incoherent motion diffusion-weighted MRI in patients with breast cancer: Correlation with tumor stroma characteristics. Eur J Radiol 2019; 120: 108686.
[http://dx.doi.org/10.1016/j.ejrad.2019.108686] [PMID: 31586850]
[27]
Noij DP, Martens RM, Marcus JT, et al. Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: A systematic review of the diagnostic and prognostic value. Oral Oncol 2017; 68: 81-91.
[http://dx.doi.org/10.1016/j.oraloncology.2017.03.016] [PMID: 28438298]
[28]
Liang CY, Chen MD, Zhao XX, Yan CG, Mei YJ, Xu YK. Multiple mathematical models of diffusion-weighted magnetic resonance imaging combined with prognostic factors for assessing the response to neoadjuvant chemotherapy and radiation therapy in locally advanced rectal cancer. Eur J Radiol 2019; 110: 249-55.
[http://dx.doi.org/10.1016/j.ejrad.2018.12.005] [PMID: 30599868]
[29]
Mürtz P, Penner AH, Pfeiffer AK, et al. Intravoxel incoherent motion model–based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma. OncoTargets Ther 2016; 9: 6425-33.
[http://dx.doi.org/10.2147/OTT.S113909] [PMID: 27799790]
[30]
Prise V, Honess D, Stratford M, Wilson J, Tozer G. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 2002; 21(4): 717-26.
[http://dx.doi.org/10.3892/ijo.21.4.717] [PMID: 12239609]
[31]
Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: Novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 2009; 90(3): 284-94.
[http://dx.doi.org/10.1111/j.1365-2613.2009.00651.x] [PMID: 19563611]
[32]
Wang H, Cona MM, Chen F, et al. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers. Anticancer Drugs 2012; 23(1): 12-21.
[http://dx.doi.org/10.1097/CAD.0b013e328349dd60] [PMID: 21857503]
[33]
Le Bihan D. What can we see with IVIM MRI? Neuroimage 2019; 187: 56-67.
[http://dx.doi.org/10.1016/j.neuroimage.2017.12.062] [PMID: 29277647]
[34]
Yuan Y, Zeng D, Zhang Y, et al. Intravoxel incoherent motion diffusion-weighted imaging assessment of microvascular characteristics in the murine embryonal rhabdomyosarcoma model. Acta radiologica (Stockholm, Sweden : 1987) 2020; 61(2): 260-6.
[http://dx.doi.org/10.1177/0284185119855731]
[35]
Song X, Wang L, Ren H, Wei R, Ren JL, Niu J. Intravoxel incoherent motion imaging in differentiation borderline from malignant ovarian epithelial tumors: Correlation With histological cell proliferation and vessel characteristics. J Magn Reson Imaging 2020; 51(3): 928-35.
[http://dx.doi.org/10.1002/jmri.26885] [PMID: 31373117]
[36]
Mita MM, Sargsyan L, Mita AC, Spear M. Vascular-disrupting agents in oncology. Expert Opin Investig Drugs 2013; 22(3): 317-28.
[http://dx.doi.org/10.1517/13543784.2013.759557] [PMID: 23316880]

Rights & Permissions Print Cite
Article Metrics
15
2
© 2024 Bentham Science Publishers | Privacy Policy